<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Angiotech Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/angiotech-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083</link>
		<comments>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[RBS]]></category>
		<category><![CDATA[Royal Bank of Scotland Group plc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43083</guid>
		<description><![CDATA[Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies to companies developing advanced pharmaceutical products, to license some of its biodegradable polymer implant technology to the Melbourne-based company. The technology is used for treating sun-induced skin disorders. The clauses of the deal were undisclosed. The two companies have been working together to develop Clinuvel&#8217;s proprietary sustained release SCENESSE (afamelanotide) implant formulation for many years. The formulation is being developed as a preventive treatment for ultraviolet (UV) and light-related dermatological deficiencies. The implant is being studied for treating a range of dermatological disorders not only in Australia but also in Europe. SurModics’ biodegradable polymer drug delivery technology permits afamelanotide to be released in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDEX) Pro-Dex &#8211; Profitability Will be the Key to Success &#8211; Undervalued?</title>
		<link>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471</link>
		<comments>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:42:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[Heska Corporation]]></category>
		<category><![CDATA[HSKA]]></category>
		<category><![CDATA[PDEX]]></category>
		<category><![CDATA[Pro-Dex Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30471</guid>
		<description><![CDATA[People who are familiar with the healthcare sector might have found a different phenomenon in the New Year that investors start switching their focus on companies which have cutting edge products and long-term profitability, like Heska Corp. (HSKA) and Angiotech Pharma (ANPI). HSKA has had more than 100% gains since last December and kept challenging $1 resistance in the past week. The stock price is still attractive at this level in view of its prospect; Although ANPI missed expectation for last quarter’s earning, it still has a 15% gain after my introduction. This reflected investors’ confidence on the company’s products and sales ability. I still will keep it on the top of my watch list. Another stock which has similar situation to HSKA and ANPI is PDEX. If you make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) Surmodics Inks Licensing Deal With Roche</title>
		<link>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337</link>
		<comments>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337#comments</comments>
		<pubDate>Fri, 09 Oct 2009 17:44:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17337</guid>
		<description><![CDATA[On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets. Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics. The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

